Skip to NavigationSkip to content


MSD's Phase 3 study of lymphoma treatment meets primary endpoints

Photo by NASA

MSD announced that its Phase 3 study of Keytruda (pembrolizumab) for the treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) met one of its dual primary endpoints of progression-free survival.

This was labbled the KEYNOTE-204 trial, which studied a random sample of 304 patients with relapsed or refractory cHL to receive either Keyruda or the anti-body drug conjugate Adcetris. In this trial, Keytruda demonstrated a significant and clinically meaningful improvement in progression-free survival compared with Adcetris.

EU approval for Roche's Polivy combo in relapsed/refractory B-cell lymphoma

The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed.

Takeda commits to advancing treatments for rare bleeding disorders and cancer

Takeda presented at the 61st American Society of Hematology (ASH) Annual Meeting, 29 company-sponsored abstracts to highlight its commitment to advancing treatments for rare bleeding disorders.

These scientific updates from the company showed off investigational and early-stage therapies as well as data from Phase 3 trials in disease states like leukemia and lymphoma.

Roche scores FDA approval for Polivy combo in diffuse large B-cell lymphoma

Roche is celebrating the decision taken by the FDA to approve its anti-CD79b antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) in combination with bendamustine and Rituxan (rituximab) (BR) as a treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in who have received at least two prior therapies.

The drug regimen was approved after being granted Accelerated Approval from the FDA. The US regulator’s decision was taken based on data derived from 80 patients ineligible for haematopoietic stem cell transplant.

FDA first as agency expands label on Celgene's Revlimid in previously treated follicular or marginal zone lymphoma

Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab product (R²) as a therapy for previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL), marking the first approval for the US regulator in these indolent forms of non-Hodgkin’s lymphoma (NHL) that does not include chemotherapy.

Phase 3 data submitted in support of the application showed that the combo therapy demonstrated a “statistically significant” improvement in median progression-free survival (PFS) compared to rituxima

NICE recommend Takeda's lymphoma treatment Adcetris

Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma (CTCL).

CTCL, a rare form of non-Hodgkin lymphoma, is in most cases incurable. Eligible patients will however, now be able to access Takeda’s treatment which has shown significant improvement in disease response comparted to current standard-of-care therapies, in clinical trials.

Novartis' CAR-T therapy Kymriah gets NICE green light in diffuse large B-cell lymphoma

NICE has announced another momentous decision for lymphoma patients in England and Wales:, recommending Novartis’ chimeric antigen receptor T cell (CAR-T) therapy Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell forms of the condition (DLBCL) who have not responded or have relapsed after two courses of chemotherapy.

It is estimated that 200 patients will be eligible to access the treatment each year in England and Wales.

Epizyme shuts down failing lymphoma trial as FDA imposes clinical hold

Epizyme’s Q2 financial results have been derailed by the company’s decision to terminate further Phase 2 development of its lead drug tazemetostat in the treatment of relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), after an interim data assessment revealed it was not effective enough to continue pursuing.

The news tore a chunk out of the company’s shares, which plunged 24%.

Celgene's Revlimid combo meets Phase 3 goal in relapsed/refractory indolent lymphoma

Celgene has lifted the curtain on new Phase 3 data for its combo of Revlimid (lenalidomide) plus rituximab (R2) in the treatment of relapsed/refractory follicular and marginal zone lymphoma, confirming that its primary endpoint was met.

Blood cancer patients over 75 are significantly underrepresented in clinical trials, study finds

The FDA’s first comprehensive analysis of clinical trial enrolment in older patients with blood cancers has revealed that the population of patients over 75 are significantly underrepresented, particularly when considering the high incidence of these conditions in this age group. Currently, one in five patients diagnosed with blood cancer is over 75, and this figure is expected to grow as the population ages.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches